Patents by Inventor Susan Champion

Susan Champion has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Labelled glutamine and lysine analogues
    Publication number: 20060292075
    Abstract: Synthetic analogues of lysine and glutamine are provided which function as substrates for the fibrin-stabilising enzyme Factor XIIIa even when labelled with a detectable moiety. The use of suitable protecting groups provides compounds which possess reduced susceptibility to in vivo metabolism especially by peptidases, and are hence useful agents for the diagnosis of thrombosis, embolism, atherosclerosis, inflammation or cancer.
    Type: Application
    Filed: April 24, 2006
    Publication date: December 28, 2006
    Inventors: Anthony Storey, Marivi Mendizabal, Susan Champion, Alex Gibson, Benedicte Guilbert, Ian Wilson, Peter Knox
  • Labelled glutamine and lysine analogues
    Patent number: 7049289
    Abstract: Synthetic analogues of lysine and glutamine are provided which function as substrates for the fibrin-stabilising enzyme Factor XIIIa even when labelled with a detectable moiety. The use of suitable protecting groups provides compounds which possess reduced susceptibility to in vivo metabolism especially by peptidases, and are hence useful agents for the diagnosis of thrombosis, embolism, atherosclerosis, inflammation or cancer.
    Type: Grant
    Filed: May 14, 1999
    Date of Patent: May 23, 2006
    Assignee: Amersham PLC
    Inventors: Anthony Eamon Storey, Marivi Mendizabal, Susan Champion, Alex Gibson, Benedicte Guilbert, Ian Andrew Wilson, Peter Knox
  • Labelled factor XIIIa substrates
    Patent number: 6897209
    Abstract: A complex of a radiometal or paramagnetic metal ion with a metal chelating agent such as a diaminedioxime has attached thereto a substituent of formula (Y)m-A-NHR)k can function as a substrate for the fibrin-stabilizing Factor XIIIa. The complex is useful for the diagnosis or therapy of thrombosis, embolism, atherosclerosis, inflammation or cancer.
    Type: Grant
    Filed: August 22, 2003
    Date of Patent: May 24, 2005
    Assignee: GE Healthcare Limited
    Inventors: Alan Michael Forster, Peter Knox, Marivi Mendizabal, Timothy Charles Richardson, Anthony Eamon Storey, Ian Andrew Wilson, Susan Champion, Alex Gibson, Benedicte Guilbert
  • Labelled ascorbic acid derivatives
    Patent number: 6749832
    Abstract: Compounds of formula (I) where: X1 is OH or SH or NH2 or —L-Z; X2 and X3 are the same or different and each is H, C1-4 alkyl, benzyl a protecting group or —L-Z, X4 is H or C1-4 alkyl, L is a linker comprising a chain of 0-10 atoms, Z is a group comprising a detectable moiety which comprise at least one detectable moiety are useful in the diagnosis and prognosis and radiotherapy of metastatic bone disease.
    Type: Grant
    Filed: September 16, 2002
    Date of Patent: June 15, 2004
    Assignee: Amersham PLC
    Inventors: Susan Champion, Richard Pither
  • Labelled factor XIIIa substrates
    Publication number: 20040076580
    Abstract: A complex of a radiometal or paramagnetic metal ion with a metal chelating agent such as a diaminedioxime has attached thereto a substituent of formula (Y)m—A—NHR)k can function as a substrate for the fibrin-stabilizing Factor XIIIa. The complex is useful for the diagnosis or therapy of thrombosis, embolism, atherosclerosis, inflammation or cancer.
    Type: Application
    Filed: August 22, 2003
    Publication date: April 22, 2004
    Applicant: AMERSHAM PLC
    Inventors: Alan Michael Forster, Peter Knox, Marivi Mendizabal, Timothy Charles Richardson, Anthony Eamon Storey, Ian Andrew Wilson, Susan Champion, Alex Gibson, Benedicte Guilbert
  • Labelled factor XIIIa substrates
    Patent number: 6653299
    Abstract: A complex of a radiometal or paramagnetic metal ion with a metal chelating agent such as a diaminedioxime has attached thereto a substituent of formula —(Y)m—A—NHR, can function as a substrate for the fibrin-stabilizing Factor XIIIa. The complex is useful for the diagnosis or therapy of thrombosis, embolism, atherosclerosis, inflammation or cancer.
    Type: Grant
    Filed: October 4, 1999
    Date of Patent: November 25, 2003
    Assignee: Nycomed Amersham PLC
    Inventors: Alan Michael Forster, Peter Knox, Marivi Mendizabal, Timothy Charles Richardson, Anthony Eamon Storey, Ian Andrew Wilson, Susan Champion, Alex Gibson, Benedicte Guilbert
  • Labelled ascorbic acid derivatives
    Publication number: 20030153736
    Abstract: Compounds of formula (I) where: X1 is OH or SH or NH2 or -L-Z; X2 and X3 are the same or different and each is H, C1-4 alkyl, benzyl a protecting group or -L-Z, X4 is H or C1-4 alkyl, L is a linker comprising a chain of 0-10 atoms, Z is a group comprising a detectable moiety which comprise at least one detectable moiety are useful in the diagnosis and prognosis and radiotherapy of metastatic bone disease.
    Type: Application
    Filed: September 16, 2002
    Publication date: August 14, 2003
    Inventors: Susan Champion, Richard Pither